RAF1 and glioblastoma: Consistent with the aforementioned RasB8p3 data, II-B08 treatment decreased the level of phosphorylated SHP2 and markedly attenuated the EGF-stimulated binding of Ras to Raf:RBD and phosphorylated level of ERK in a dose-dependent manner in U87 and U87-viii GBM cells, which harbour hyperactive, but otherwise WT, Ras (Fig. 5a and Supplementary Fig. 8).